News & Updates

IM noninferior to IV sotrovimab for COVID-19
IM noninferior to IV sotrovimab for COVID-19
17 Feb 2022 byAudrey Abella

In high-risk nonhospitalized patients with mild-to-moderate COVID-19, intramuscular administration of the monoclonal antibody sotrovimab was noninferior to IV infusion of the drug, according to findings from the phase III COMET-TAIL trial presented at CROI 2022.

IM noninferior to IV sotrovimab for COVID-19
17 Feb 2022
Young carers suffer heavy mental health burden during pandemic
Young carers suffer heavy mental health burden during pandemic
16 Feb 2022

The coronavirus disease 2019 (COVID-19) pandemic has worsened mental health outcomes among adolescents who care for family members or friends, reports a recent UK study. Psychosocial risk factors before and during the pandemic may explain such burden.

Young carers suffer heavy mental health burden during pandemic
16 Feb 2022
COVID-19 infection relatively rare in vaccinated IBD patients
COVID-19 infection relatively rare in vaccinated IBD patients
15 Feb 2022 byRoshini Claire Anthony

Patients with inflammatory bowel disease (IBD) who have completed a COVID-19 vaccine regimen have a low risk of developing COVID-19, though receipt of mRNA vaccines may offer better protection, according to a small study presented at the Crohn’s and Colitis Congress 2022.

COVID-19 infection relatively rare in vaccinated IBD patients
15 Feb 2022
COVID-19 more likely in haemodialysis patients
COVID-19 more likely in haemodialysis patients
14 Feb 2022
Delaying endoscopies due to COVID-19 safe in IBD patients
Delaying endoscopies due to COVID-19 safe in IBD patients
14 Feb 2022 byTristan Manalac

Delays in endoscopies due to the coronavirus disease 2019 (COVID-19) pandemic does not seem to worsen clinical outcomes in patients with inflammatory bowel diseases (IBD), though healthcare utilization patterns appear to be affected, according to a study reported at the recently concluded 2022 Crohn’s & Colitis Congress (CCC 2022).

Delaying endoscopies due to COVID-19 safe in IBD patients
14 Feb 2022
Antiretroviral therapy with INSTI maintains low switch rates among people with HIV
Antiretroviral therapy with INSTI maintains low switch rates among people with HIV
13 Feb 2022

Persons living with HIV (PLWH) often switch from first-line antiretroviral therapies (ART) of non-nucleoside reverse transcriptase inhibitors (NNRTIs) or protease inhibitors (PI) to second-line integrase strand transfer inhibitors (INSTI), a recent Japan study has found. PLWHs tend to stay on INSTIs for a long time thereafter.

Antiretroviral therapy with INSTI maintains low switch rates among people with HIV
13 Feb 2022